Skip to main content

Table 3 Paclitaxel pharmacokinetics

From: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

Ganetespib (mg/m2) Number Cmax Tmax T1/2 AUC CL MRT
(ng/ml) (hours) (hours) (h*ng/ml) (L/h/m2) (hours)
100 3 3340 ± 1270 0.8 ± 0.3 12.9 ± 0.4 5900 ± 1440 14.2 ± 3.5 8.5 ± 0.8
150 6 3750 ± 1370 1.0 ± 0.0 13.6 ± 3.3 6280 ± 1430 13.4 ± 3.2 9.0 ± 4.0
  1. Cmax maximum serum concentration, Tmax time of maximum serum concentration observed, T 1/2 half-life AUC area under the curve, CL clearance, MRT mean resident time